Pembrolizumab-Induced Immune-Mediated Liver Injury:a Retrospective Study and Review of the Literature
Objective:To retrospectively analyze the clinical characteristics and risk factors of liver injury caused by pembrolizumab,so as to provide reference for clinical safe drug use.Methods:Case reports of hepatitis caused by pembrolizumab in China National Knowledge Infrastructure(CNKI),Wanfang Medical Network,VIP,China BioMedical Literature Network,PubMed,Science Direct,Wiley,Springer and other databases were searched for induction and analysis.Results:A total of 28 cases of liver injury caused by pembrolizumab were reported,most of them were males(57.1％),aged 51～70 years(60.7％),and most of them occurred within 30 days after treatment(57.2％).Cholestasis was the most common type of liver injury,and the degree of injury was grade mostly grade 3～4.Most patients(78.6％)improved or recovered after drug withdrawal and treatment.Conclusion:During the application of pembrolizumab,clinicians should closely monitor the patient's liver function to avoid serious liver injury and ensure the clinical safety of drug use.
NETL
NSTL
万方数据
维普
